نتائج البحث

Paxlovid for the treatment of COVID-19: a systematic review and meta-analysis.

• Authors : Wang Y; Department of Cardiology, Shidong Hospital, Yangpu District, Shidong Hospital affiliated to University of Shanghai for Science and Technology, 999 Shiguang Road, Shanghai 200438, China.; Yang Y

Subjects: Antiviral Agents*/Antiviral Agents*/Antiviral Agents*/therapeutic use ; COVID-19*/COVID-19*/COVID-19*/diagnosis ; COVID-19*/COVID-19*/COVID-19*/mortality

• Source: Journal of infection in developing countries [J Infect Dev Ctries] 2024 Aug 31; Vol. 18 (8), pp. 1169-1178. Date of Electronic Publication: 2024 Aug 31.Publisher: Open Learning on Enteric Pathogens Country of Publication: Italy NLM ID: 101305410 Publication Model: Electronic Cited Medium: Internet

تفاصيل العنوان

Pharmacokinetics, Safety, and Bioequivalence of 2 Lopinavir/Ritonavir (200/50 mg) Tablets in Healthy Chinese Volunteers: Effect of Food on Absorption.

• Authors : Zhang W; Department of Clinical Pharmacology, The Second Hospital of Anhui Medical University, Hefei, China.; Lin L

Subjects: Lopinavir*/Lopinavir*/Lopinavir*/pharmacokinetics ; Ritonavir*/Ritonavir*/Ritonavir*/pharmacokinetics; Humans

• Source: Clinical pharmacology in drug development [Clin Pharmacol Drug Dev] 2023 Jun; Vol. 12 (6), pp. 602-610. Date of Electronic Publication: 2023 Feb 15.Publisher: Wiley Country of Publication: United States NLM ID: 101572899 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

تفاصيل العنوان

艾可清对药物代谢酶活性及对洛匹那韦与利托那韦的大鼠血浆 药代动力学参数的影响.

• Authors : 何晓峰¹ ; 卢元媛² ; 陈剑涛²

• Source: Traditional Chinese Drug Research & Clinical Pharmacology. Jul2024, Vol. 35 Issue 7, p1046-1054. 9p.

تفاصيل العنوان

Lopinavir/Ritonavir in PLWH With High-Grade AIN

• Authors : Wisconsin Partnership Program

• Source: A Phase I Study of Intra-anally Administered Lopinavir/Ritonavir in People Living With HIV (PLWH) With High-Grade Anal Intraepithelial

تفاصيل العنوان

Observational study of the effects of Favipiravir vs Lopinavir/Ritonavir on clinical outcomes in critically Ill patients with COVID-19.

• Authors : Kocayiğit H; Department of Anaesthesiology and Reanimation, Sakarya University Education and Research Hospital, Sakarya, Turkey.; Özmen Süner K

Subjects: Amides*/Amides*/Amides*/administration & dosage ; Amides*/Amides*/Amides*/adverse effects ; COVID-19*/COVID-19*/COVID-19*/diagnosis

• Source: Journal of clinical pharmacy and therapeutics [J Clin Pharm Ther] 2021 Apr; Vol. 46 (2), pp. 454-459. Date of Electronic Publication: 2020 Oct 31.Publisher: Country of Publication: England NLM ID: 8704308 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1365-2710

تفاصيل العنوان

Comparative effectiveness of Lopinavir/Ritonavir-based regimens in COVID-19.

• Authors : Qu J; Department of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha, China.; Institute of Clinical Pharmacy, Central South University, Changsha, China.

Subjects: COVID-19 Drug Treatment*; Lopinavir/Lopinavir/Lopinavir/*pharmacology ; Ritonavir/Ritonavir/Ritonavir/*pharmacology

• Source: Clinical and experimental pharmacology & physiology [Clin Exp Pharmacol Physiol] 2021 Feb; Vol. 48 (2), pp. 203-210. Date of Electronic Publication: 2020 Nov 07.Publisher: Wiley-Blackwell Country of Publication: Australia NLM ID: 0425076 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

تفاصيل العنوان

Evaluation of the efficacy and safety of favipiravir and interferon compared to lopinavir/ritonavir and interferon in moderately ill patients with COVID-19: a structured summary of a study protocol for a randomized controlled trial.

• Authors : Hassaniazad M; Infectious and Tropical Diseases Research Center, Hormozgan Health Institute, Hormozgan University of Medical Sciences, Bandar Abbas, Iran.; Bazram A

Subjects: Amides*/Amides*/Amides*/administration & dosage ; Amides*/Amides*/Amides*/adverse effects ; Coronavirus Infections*/Coronavirus Infections*/Coronavirus Infections*/diagnosis

• Source: Trials [Trials] 2020 Oct 27; Vol. 21 (1), pp. 886. Date of Electronic Publication: 2020 Oct 27.Publisher: BioMed Central Country of Publication: England NLM ID: 101263253 Publication Model: Electronic Cited Medium: Internet ISSN: 1745-6215

تفاصيل العنوان

Treatment of Middle East respiratory syndrome with a combination of lopinavir/ritonavir and interferon-β1b (MIRACLE trial): statistical analysis plan for a recursive two-stage group sequential randomized controlled trial.

• Authors : Arabi YM; and the Saudi Critical Care Trials group

Subjects: Antiviral Agents/Antiviral Agents/Antiviral Agents/*therapeutic use ; Coronavirus Infections/Coronavirus Infections/Coronavirus Infections/*drug therapy ; Interferon beta-1b/Interferon beta-1b/Interferon beta-1b/*therapeutic use

• Source: Trials [Trials] 2020 Jan 03; Vol. 21 (1), pp. 8. Date of Electronic Publication: 2020 Jan 03.Publisher: BioMed Central Country of Publication: England NLM ID: 101263253 Publication Model: Electronic Cited Medium: Internet ISSN: 1745-6215

تفاصيل العنوان

Severe COVID-19 infection in a kidney transplant recipient treated with lopinavir/ritonavir, hydroxychloroquine and dexamethasone.

• Authors : Suryantoro SD; Department of Internal Medicine, Faculty of Medicine Airlangga University, Airlangga University Hospital, Surabaya, Indonesia.; Thaha M

Subjects: COVID-19 Drug Treatment*; Dexamethasone/Dexamethasone/Dexamethasone/*therapeutic use ; Hydroxychloroquine/Hydroxychloroquine/Hydroxychloroquine/*therapeutic use

• Source: Journal of infection in developing countries [J Infect Dev Ctries] 2021 Sep 30; Vol. 15 (9), pp. 1257-1262. Date of Electronic Publication: 2021 Sep 30.Publisher: Open Learning on Enteric Pathogens Country of Publication: Italy NLM ID: 101305410 Publication Model: Electronic Cited Medium: Internet

تفاصيل العنوان

The Australasian COVID-19 Trial (ASCOT) to assess clinical outcomes in hospitalised patients with SARS-CoV-2 infection (COVID-19) treated with lopinavir/ritonavir and/or hydroxychloroquine compared to standard of care: A structured summary of a study protocol for a randomised controlled trial.

• Authors : Denholm JT; Davis J ...

Subjects: COVID-19* ; COVID-19 Drug Treatment* ; Hydroxychloroquine*/Hydroxychloroquine*/Hydroxychloroquine*/administration & dosage

• Source: Trials [Trials] 2020 Jul 14; Vol. 21 (1), pp. 646. Date of Electronic Publication: 2020 Jul 14.Publisher: BioMed Central Country of Publication: England NLM ID: 101263253 Publication Model: Electronic Cited Medium: Internet ISSN: 1745-6215

تفاصيل العنوان